-+ 0.00%
-+ 0.00%
-+ 0.00%

bioAffinity wins Hong Kong patent for CyPath Lung cancer diagnostic technology

PUBT·09/17/2026 12:01:15
Listen to the news
bioAffinity wins Hong Kong patent for CyPath Lung cancer diagnostic technology
  • bioAffinity Technologies won a Hong Kong patent covering its CyPath Lung platform for noninvasive lung cancer risk assessment from sputum samples.
  • Protection in Hong Kong follows a China patent granted in 2025, strengthening the company’s intellectual property position for an Asia expansion.
  • The patent covers use of fluorescent markers with flow cytometry to identify cell populations linked to lung cancer in sputum.
  • Management cited Asia’s roughly 1.6 million new lung cancer cases a year as a key commercial driver for the test.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609170800BIZWIRE_USPR_____20260917_BW849195) on September 17, 2026, and is solely responsible for the information contained therein.